A letter from Jack Wood at Cutter stated that Cutter felt it was prudent to no longer effect sales of non-heat-treated product for use in the UK following dramatic changes in the UK regarding heat-treated Factor 8 products.
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Viral Inactivation
Key Person(s)
Jack Wood